Skip to main content

Animations

MJFF Publications

6981 - 6990 of 8808 Results
Title
Year
  • Year
  • 2022
  • 2014
  • 2020
  • 2021
  • 2022
  • 2023
  • 2020
  • 2021
  • 2021
  • 2023
  • Summary Details
    OPEN
    Title: Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson’s disease
    Journal Name: Molecular Neurodegeneration
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1186/s13024-022-00520-4
    Citation Count: 15
  • Summary Details
    OPEN
    Title: Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinson's disease subjects
    Journal Name: Neuroscience Letters
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neulet.2014.04.027
    Citation Count: 130
  • Summary Details
    OPEN
    Title: Human plasma biomarker responses to inhalational general anaesthesia without surgery
    Journal Name: British Journal of Anaesthesia
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.bja.2020.04.085
    Citation Count: 40
  • Summary Details
    OPEN
    Title: Poly (ADP-ribose) Interacts With Phosphorylated α-Synuclein in Post Mortem PD Samples
    Journal Name: Frontiers in Aging Neuroscience
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fnagi.2021.704041
    Citation Count: 23
  • Summary Details
    OPEN
    Title: Small molecule C381 targets the lysosome to reduce inflammation and ameliorate disease in models of neurodegeneration
    Journal Name: Proceedings of the National Academy of Sciences
    Publisher: Proceedings of the National Academy of Sciences
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd, cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1073/pnas.2121609119
    Citation Count: 40
  • Summary Details
    OPEN
    Title: Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update
    Journal Name: Journal of Parkinson’s Disease
    Publisher: SAGE Publications
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.3233/jpd-239901
    Citation Count: 62
  • Summary Details
    OPEN
    Title: ATP13A3 is a major component of the enigmatic mammalian polyamine transport system
    Journal Name: Journal of Biological Chemistry
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1074/jbc.ra120.013908
    Citation Count: 69
  • Summary Details
    OPEN
    Title: Novel Thienopyrimidine-Based PET Tracers for P2Y12 Receptor Imaging in the Brain
    Journal Name: ACS Chemical Neuroscience
    Publisher: American Chemical Society (ACS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1021/acschemneuro.1c00641
    Citation Count: 26
  • Summary Details
    OPEN
    Title: CD4 + T cells contribute to neurodegeneration in Lewy body dementia
    Journal Name: Science
    Publisher: American Association for the Advancement of Science (AAAS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1126/science.abf7266
    Citation Count: 200
  • Summary Details
    OPEN
    Title: LINE-1 retrotransposons drive human neuronal transcriptome complexity and functional diversification
    Journal Name: Science Advances
    Publisher: American Association for the Advancement of Science (AAAS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc, cc-by, cc-by
    DOI - Digital Object Identifier: 10.1126/sciadv.adh9543
    Citation Count: 54
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.